supplementary table 3.
Primary outcomes included efficacy of ciprofol (Satisfaction evaluation for anesthesiologists, Time to full alertness, Time to successful anesthesia induction, Time to loss of eyelash reflex, Success rate of anesthesia, Time required for patients to leave the post-anesthesia care unit (PACU), Time to respiratory recovery) on anesthesia induction and maintenance in comparison to propofol.
Secondary outcomes included the safety profile of ciprofol (total adverse events, tachycardia, rash, prolonged QT interval, pain on injection (induction), hypoxia, hypotension, hypertension (induction), CTCAE severity scale (grade 1) (induction), CTCAE severity scale (grade 2) (induction), bradycardia (induction), any treatment-emergent adverse event, 0.4 mg number of patients who maintained BIS between 40-60 (min) and 0.4 mg elevated AST (induction and maintenance). This is shown in